BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 27890075)

  • 21. IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas.
    Gachard N; Parrens M; Soubeyran I; Petit B; Marfak A; Rizzo D; Devesa M; Delage-Corre M; Coste V; Laforêt MP; de Mascarel A; Merlio JP; Bouabdhalla K; Milpied N; Soubeyran P; Schmitt A; Bordessoule D; Cogné M; Feuillard J
    Leukemia; 2013 Jan; 27(1):183-9. PubMed ID: 22944768
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
    Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
    Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Composite monoclonal B-cell lymphocytosis and MYD88 L265P-positive lymphoplasmacytic lymphoma in a patient with IgM light chain amyloidosis: Case report.
    Oishi N; Inoue T; Odate T; Mochizuki K; Ohashi K; Kirito K; Kondo T
    Pathol Int; 2020 Jul; 70(7):458-462. PubMed ID: 32323419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of MYD88 L265P mutations in formalin-fixed and decalcified BM biopsies from patients with lymphoplasmacytic lymphoma.
    Capaldi IB; May AM; Schmitt-Graeff A; Follo M; Aumann K; Kayser G; Perazzo JC; Werner M; Fisch P
    Exp Mol Pathol; 2014 Aug; 97(1):57-65. PubMed ID: 24842316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.
    Xu L; Hunter ZR; Tsakmaklis N; Cao Y; Yang G; Chen J; Liu X; Kanan S; Castillo JJ; Tai YT; Zehnder JL; Brown JR; Carrasco RD; Advani R; Sabile JM; Argyropoulos K; Lia Palomba M; Morra E; Trojani A; Greco A; Tedeschi A; Varettoni M; Arcaini L; Munshi NM; Anderson KC; Treon SP
    Br J Haematol; 2016 Mar; 172(5):735-44. PubMed ID: 26659815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Waldenström macroglobulinemia.
    Treon SP; Hunter ZR; Castillo JJ; Merlini G
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):945-70. PubMed ID: 25212891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MYD88 L265P mutation analysis is a useful diagnostic adjunct for lymphoplasmacytic lymphoma with pleural effusion.
    Pan ST; Wang RC; Kuo CC; Hsieh YC; Su YZ; Chuang SS
    Pathol Int; 2019 Oct; 69(10):601-607. PubMed ID: 31556196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An unusual case of cutaneous Waldenström macroglobulinemia with the MYD88 L265P mutation.
    Minzenmayer AN; Miranda RN; Powell PR; Parekh PK
    J Cutan Pathol; 2020 Sep; 47(9):850-853. PubMed ID: 32335928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.
    Xu L; Hunter ZR; Yang G; Zhou Y; Cao Y; Liu X; Morra E; Trojani A; Greco A; Arcaini L; Varettoni M; Brown JR; Tai YT; Anderson KC; Munshi NC; Patterson CJ; Manning RJ; Tripsas CK; Lindeman NI; Treon SP
    Blood; 2013 Mar; 121(11):2051-8. PubMed ID: 23321251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significance of MYD88 L265P Mutation Status in the Subclassification of Low-Grade B-Cell Lymphoma/Leukemia.
    Insuasti-Beltran G; Gale JM; Wilson CS; Foucar K; Czuchlewski DR
    Arch Pathol Lab Med; 2015 Aug; 139(8):1035-41. PubMed ID: 26230596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells.
    Sewastianik T; Guerrera ML; Adler K; Dennis PS; Wright K; Shanmugam V; Huang Y; Tanton H; Jiang M; Kofides A; Demos MG; Dalgarno A; Patel NA; Nag A; Pinkus GS; Yang G; Hunter ZR; Jarolim P; Munshi NC; Treon SP; Carrasco RD
    Blood Adv; 2019 Nov; 3(21):3360-3374. PubMed ID: 31698464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic Tools of Waldenströms Macroglobulinemia - Best Possibilities for Non-invasive and Long-term Disease Monitoring.
    Growkova K; Kufová Z; Sevcikova T; Filipová J; Kascak M; Jelínek T; Grosicki S; Barchnicka A; Roziaková Ľ; Mistrík M; Simicek M; Hájek R
    Klin Onkol; 2017; 30(Supplementum2):81-91. PubMed ID: 28903575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma.
    Hamadeh F; MacNamara SP; Aguilera NS; Swerdlow SH; Cook JR
    Mod Pathol; 2015 Apr; 28(4):564-74. PubMed ID: 25216226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of MYD88 in lymphoplasmacytic lymphoma diagnosis and pathogenesis.
    Rossi D
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):113-8. PubMed ID: 25696843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Successful detection of MYD88 L265P mutation in Waldenström's macroglobulinemia complicated with myelofibrosis using highly sensitive digital PCR].
    Nawata R; Sugiyama A; Harada K; Shinohara K; Yujiri T
    Rinsho Ketsueki; 2019; 60(8):903-909. PubMed ID: 31484887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency of MYD88 L256P mutation and its correlation with clinico-hematological profile in mature B-cell neoplasm.
    Shekhar R; Naseem S; Binota J; Varma N; Malhotra P
    Hematol Oncol Stem Cell Ther; 2021 Sep; 14(3):231-239. PubMed ID: 33217360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas.
    Shin SY; Lee ST; Kim HY; Park CH; Kim HJ; Kim JW; Kim SJ; Kim WS; Kim SH
    Blood Res; 2016 Sep; 51(3):181-186. PubMed ID: 27722129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Digital PCR in bone marrow trephine biopsies is highly sensitive for MYD88
    Willenbacher E; Willenbacher W; Wolf DG; Zelger B; Peschel I; Manzl C; Haun M; Brunner A
    Br J Haematol; 2019 Jul; 186(1):189-191. PubMed ID: 30763982
    [No Abstract]   [Full Text] [Related]  

  • 39. [Evaluation of clinical characteristics, MYD88(L265P) mutation, CXCR4(WHIM) mutation and prognosis in Waldenström macroglobulinemia: A single center retrospective study of 93 patients].
    Cao XX; Meng Q; Cai H; Mao YY; Duan MH; Zhu TN; Zhang W; Han B; Zhuang JL; Cai HC; Chen M; Feng J; Han X; Zhang Y; Yang C; Zhang L; Zhou DB; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):494-498. PubMed ID: 28655092
    [No Abstract]   [Full Text] [Related]  

  • 40. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.
    Varettoni M; Arcaini L; Zibellini S; Boveri E; Rattotti S; Riboni R; Corso A; Orlandi E; Bonfichi M; Gotti M; Pascutto C; Mangiacavalli S; Croci G; Fiaccadori V; Morello L; Guerrera ML; Paulli M; Cazzola M
    Blood; 2013 Mar; 121(13):2522-8. PubMed ID: 23355535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.